Shanghai-based Micurx Pharmaceuticals Inc. is preparing to file an NDA for its lead antibacterial candidate, contezolid, with China's National Medical Products Administration after results of a pivotal phase III trial there showed the drug providing comparable clinical cure rates to linezolid for complicated skin and soft tissue infections (cSSTI). Reduced hematologic toxicity for the tablet-based antibiotic vs. linezolid was also seen, highlighting one of contezolid's key advantages. Read More
As is often the case, it was a personal and devastating encounter with disease that brought Paul Mischel, a founder of newly launched Boundless Bio Inc., to the life sciences. When he lost his father to cancer, he dedicated his career to finding a cure. Read More
SEOUL, South Korea – Biotech investors in South Korea are carefully assessing the outlook for the industry after a series of scandals and reverses have rocked a sector touted as a key area for development in the country. Read More
In the world of cancer genomics, mutational hotspots and cancer drivers are used somewhat interchangeably. "It was common knowledge... that if you see a site [mutated] in many cancers, that site is a driver," Gad Getz told BioWorld. But Getz, who is director of the Cancer Genome Computational Analysis Group at the Broad Institute of MIT and Harvard, and his team argue that the conventional wisdom is incorrect. Read More
Although various government incentives have been introduced in the past few years to encourage and support more research and development designed to accelerate the discovery of new antibiotics, they, in themselves, have not been enough. Read More
Caribou Biosciences Inc., of Berkeley, Calif., granted Oxford Nanopore Ltd., of Oxford, U.K., a worldwide, nonexclusive license under foundational CRISPR/Cas9 intellectual property controlled by Caribou for nanopore sequencing. CRISPR/Cas9-mediated enrichment for nanopore sequencing enables targeted sequencing and is designed to reduce cost, data output and turnaround time. Read More
The Biosimilars Working Group, made up of diverse patient advocacy organizations, is speaking out against a decision by Canada's British Columbia provincial government to no longer cover Remicade (infliximab, Johnson & Johnson) in treating inflammatory bowel disease. Read More
Biocurepharm Korea, a subsidiary of Biocure Technology Corp., of Vancouver, British Columbia, closed a convertible debt financing. The company grossed CA$445,600 (US$335,000) issuing 4 units at CA$111,400 per unit. Read More
Although House Speaker Nancy Pelosi (D-Calif.) has yet to release the actual text of her Lower Drug Prices Now Act, the Democrat plan, unveiled in summary form Thursday, is being fast-tracked through the House with a hearing scheduled Wednesday before the Energy and Commerce Committee. Read More
